Prelude Therapeutics (PRLD) Other Non-Current Liabilities (2019 - 2026)

Prelude Therapeutics (PRLD) has 7 years of Other Non-Current Liabilities data on file, last reported at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 8.22% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (down 8.22% YoY), and the FY2025 full-year result was $2.8 million, down 8.06% from the prior year.
• Other Non-Current Liabilities declined to $2.8 million in Q1 2026, from $2.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $3.4 million in Q4 2022 to a low of $2.4 million in Q1 2022.
• A 5-year average of $3.1 million and a median of $3.2 million in 2024 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities jumped 40.04% in 2023 and slipped 8.22% in 2026, its largest moves.
• Tracing PRLD's Other Non-Current Liabilities over 5 years: stood at $3.4 million in 2022, then decreased by 0.65% to $3.3 million in 2023, then decreased by 7.46% to $3.1 million in 2024, then fell by 8.06% to $2.8 million in 2025, then fell by 2.18% to $2.8 million in 2026.
• Business Quant data shows PRLD's Other Non-Current Liabilities at $2.8 million in Q1 2026, $2.8 million in Q4 2025, and $2.9 million in Q3 2025.